SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment
Authors:
- 16 November 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 29 (4) , 452-459
Abstract
Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown in clinical trials to increase serum Mg2+ levels in patients with type 2 diabetes mellitus. However, it is unclear whether this effect is similarly observed in patients with chronic kidney disease (CKD) and whether such an increase is observed immediately after treatment. Methods Our retrospective observational study included the 62 patients with CKD who started SGLT2 inhibitor therapy at our institution between 2017 and 2022 and who had complete data on serum Mg2+ measurements at baseline and at 1, 3, and 6 months after treatment. Patients were divided into three subgroups, stratified by serum Mg2+ levels at baseline. We evaluated the changes in serum Mg2+ levels from baseline to 6 months after treatment and the factors associated with these changes. Results Median eGFR and mean serum Mg2+ at baseline were 33.5 mL/min/1.73 m2 and 2.03 mg/dL, respectively. Treatment with SGLT2 inhibitors significantly increased serum Mg2+ levels immediately from 1 month after treatment compared with those at baseline and persisted over 6 months, with an overall mean change of 0.13 mg/dL from baseline to 6 months. This increased effect was observed in the low and middle tertile subgroups, but not in the high tertile subgroup. Multivariate linear regression analysis revealed that baseline serum Mg2+ levels and sodium-chloride differences, as a parameter of acid–base status, were independently associated with these changes. Conclusions SGLT2 inhibitors increased serum Mg2+ levels in patients with CKD, particularly those with lower baseline Mg2+ levels, potentially improving their prognosis.Keywords
This publication has 20 references indexed in Scilit:
- Association of serum magnesium levels with renal prognosis in patients with chronic kidney diseaseClinical and Experimental Nephrology, 2024
- SGLT2 Inhibitors in Management of Severe Hypomagnesemia in Patients Without Diabetes: A Report of 4 CasesKidney Medicine, 2023
- Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 CasesKidney Medicine, 2022
- SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 PatientsKidney Medicine, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trialsJournal of Diabetes and its Complications, 2019
- Sodium-Chloride Difference as a Simple Parameter for Acid-Base Status AssessmentAmerican Journal of Kidney Diseases, 2017
- Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled TrialsDiabetes Therapy, 2017
- Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trialsDiabetologia, 2016
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009